Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2022-05-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
关于调整2022年限制性股票激励计划激励对象名单和授予权益数量的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding adjustments to the 2022 restricted stock incentive plan, specifically changes to the list of incentive recipients and the number of granted shares. It details board and supervisory approvals, legal opinions, and the impact of the adjustments. The document is relatively short (3050 characters) and focuses on corporate governance and equity incentive plan adjustments rather than financial results or detailed financial statements. It does not contain financial data or earnings information, nor is it a full annual or interim report. It is not a proxy solicitation or voting result announcement. The content fits best under a regulatory announcement category related to management and governance changes but is not a direct management report or remuneration report. Given the nature of the announcement about stock incentive plan adjustments and related approvals, the best fitting category is Regulatory Filings (RNS), as it is a formal regulatory disclosure about corporate governance matters that do not fit other more specific categories.
2022-05-16 Chinese
第四届监事会第三十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of Tianjin Ruipu Biotechnology Co., Ltd. It details decisions regarding adjustments to a 2022 restricted stock incentive plan, including approval of the incentive object list and the granting of restricted stock. The document includes voting results and compliance statements but does not contain financial statements or detailed financial analysis. It is a corporate governance-related announcement about board/supervisory decisions rather than a full management report or financial report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2022-05-16 Chinese
监事会关于2022年限制性股票激励计划授予日激励对象名单的核查意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from the Supervisory Board regarding the verification of the list of incentive recipients for a 2022 restricted stock incentive plan. It discusses compliance with relevant laws and regulations, adjustments to the number of incentive recipients and shares granted, and confirms the eligibility of the recipients. There is no financial data, earnings information, or report publication announcement. The content relates to management decisions and governance around stock incentives, which aligns with Board/Management Information filings. The document is relatively short and does not contain financial statements or detailed financial analysis, so it is not an Annual Report or Interim Report. It is not a proxy solicitation or voting result announcement. Therefore, the best fit is Board/Management Information (MANG).
2022-05-16 Chinese
北京市康达律师事务所关于天津瑞普生物技术股份有限公司2022年限制性股票激励计划相关调整与授予事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 restricted stock incentive plan adjustments and grant matters of Tianjin Ruipu Biotechnology Co., Ltd. It contains detailed legal analysis, references to company board and shareholder meetings, approval and authorization processes, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a stock incentive plan. It is not a simple announcement or certification but a substantive legal opinion document. This fits best under the category of Regulatory Filings (RNS) as it is a legal opinion letter related to corporate governance and compliance matters, not a direct financial or management report or a proxy solicitation. The document length (6530 characters) and content confirm it is not a brief announcement or a full annual/interim report.
2022-05-16 Chinese
独立董事对第四届董事会第三十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on adjustments to a 2022 restricted stock incentive plan and the granting of restricted shares. It references compliance with stock exchange listing rules and company articles, and discusses the legality and appropriateness of the stock incentive plan. The document is a formal opinion related to board decisions on stock incentives, not a full financial report or earnings release. It is not a report publication announcement or certification letter. It fits best under Board/Management Information (MANG) as it relates to board-level decisions and management incentives.
2022-05-16 Chinese
北京市康达律师事务所关于天津瑞普生物技术股份有限公司2022年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and voting results of the 2022 first extraordinary general meeting (EGM) of Tianjin Ruipu Biotechnology Co., Ltd. It details the meeting's call, attendance, voting procedures, and results, and confirms their legality and compliance with relevant laws and company articles. The document is not a report of financial results, audit, or management discussion, nor is it a notice or announcement of a report. It is a legal opinion on the shareholder meeting and its voting outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting (AGM or EGM). The document length is 4766 characters, sufficient to contain substantive content rather than a brief announcement. Therefore, the correct classification is DVA with high confidence.
2022-05-16 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.